-+ 0.00%
-+ 0.00%
-+ 0.00%

DNB Carnegie Trims Genmab PT, Maintains Hold Rating

MT Newswires·12/30/2025 07:12:23
Listen to the news
07:12 AM EST, 12/30/2025 (MT Newswires) -- DNB Carnegie on Tuesday decreased the price target for Danish biotechnology company Genmab (GMAB.CO) to 1,985 Danish kroner from 2,050 kroner and kept its hold rating. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)